featured
Dabrafenib Plus Trametinib for Relapsed/Refractory BRAF V600–Mutant Pediatric High-Grade Glioma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma
J. Clin. Oncol 2023 Aug 29;[EPub Ahead of Print], DR Hargrave, K Terashima, J Hara, UR Kordes, SA Upadhyaya, F Sahm, E Bouffet, RJ Packer, O Witt, L Sandalic, A Kieloch, M Russo, KJ CohenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.